New Metabolic Target & Metabolic Marker Suggest a Way Forward in Metabolic Associated Steatotic Liver Disease (MASLD)

Time: 1:00 pm
day: Seminar B PM tracks


  • New view of the pathophysiology of MASLD/MASH: further examing Phase 2b data for an insulin sensitizer with a newly appreciated mitochondrial target
  • Fasting hyperinsulinemia as an addressable marker for reduced liver function leading to disease progression
  • Exploring metabolic reprogramming in multiple cell types to address multi-organ involvement in the pathology